GSA Capital Partners LLP Acquires 934,649 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

GSA Capital Partners LLP lifted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 2,962.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 966,202 shares of the biopharmaceutical company's stock after buying an additional 934,649 shares during the period. GSA Capital Partners LLP owned approximately 0.42% of Sangamo Therapeutics worth $634,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Point72 Asset Management L.P. acquired a new position in Sangamo Therapeutics in the 4th quarter worth approximately $2,316,000. Geode Capital Management LLC lifted its stake in Sangamo Therapeutics by 3.4% in the 4th quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock worth $2,257,000 after acquiring an additional 73,540 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Sangamo Therapeutics during the 4th quarter valued at about $1,744,000. Two Sigma Investments LP increased its holdings in shares of Sangamo Therapeutics by 222.1% in the 4th quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company's stock valued at $1,033,000 after purchasing an additional 698,296 shares during the period. Finally, Acuta Capital Partners LLC acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter worth approximately $755,000. 56.93% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on SGMO shares. Barclays lowered their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen lowered Sangamo Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, May 30th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, June 24th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $4.50.

Sangamo Therapeutics Trading Down 5.5%

NASDAQ:SGMO traded down $0.03 during mid-day trading on Thursday, hitting $0.50. 3,710,921 shares of the company's stock traded hands, compared to its average volume of 6,013,581. Sangamo Therapeutics, Inc. has a 12 month low of $0.41 and a 12 month high of $3.18. The firm has a market capitalization of $116.82 million, a price-to-earnings ratio of -1.29 and a beta of 1.18. The firm has a 50 day moving average of $0.52 and a two-hundred day moving average of $0.74.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. The company had revenue of $6.44 million during the quarter, compared to the consensus estimate of $7.90 million. As a group, equities research analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.